Instrument Inactif

Communiqués CureVac Deutsche Boerse AG

Actions

5CV

NL0015436031

Communiqués

26/11	CureVac Announces Voting Results of Extraordinary General Meeting	EQ
24/11	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates	EQ
24/10/25	CureVac N : Convening Notice EGM 25 November 2025	PU
24/10/25	CureVac N : Proxy Card EGM 25 November 2025	PU
24/10/25	CureVac N : Merger Proposal	PU
24/10/25	CureVac N : Explanatory Notes to the Merger Proposal	PU
15/08/25	CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates	EQ
08/08/25	CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech	EQ
24/06/25	CureVac N : Pressemitteilung	PU
24/06/25	CureVac Announces Voting Results of General Meeting	EQ
23/05/25	CureVac N : Proxy Card AGM 2025	PU
23/05/25	CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2024	PU
23/05/25	CureVac N : Proxycard AGM 2025	PU
20/05/25	CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates	EQ
15/05/25	CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE	EQ
22/04/25	CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Transcript	PU
10/04/25	CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Presentation	PU
10/04/25	CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update	EQ
08/04/25	CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025	EQ
07/04/25	CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer	EQ
27/03/25	CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE	EQ
18/02/25	CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators	EQ
12/11/24	CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Form 6 K	PU
12/11/24	CureVac N : Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Form 6 K	PU
12/11/24	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update	EQ